TriangleHEALTH PROFESSIONAL · SOURCE READING
Chemotherapy
Source: Childhood Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 16, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Childhood Mesothelioma
The European Cooperative Study Group on Pediatric Rare Tumors retrospectively reviewed children, adolescents, and young adults (aged ≤21 years) with mesotheliomas who were treated between 1987 and 2018.[5] Investigators identified 15 male patients and 18 female patients with mesotheliomas. Only one patient had a documented asbestos exposure. In most patients, the primary tumor was located in the peritoneum (23 patients). Tumor histologies were either multicystic mesothelioma of the peritoneum (6 patients) or malignant mesothelioma (27 patients).
Source links and citations
The response rate to treatment with cisplatin-pemetrexed was 50% (6 of 12 cases).
After a median follow-up period of 6.7 years (range, 0–20 years), the 5-year overall survival rate was 82.3%, and the event-free survival rate was 45.1%.
All patients with multicystic mesothelioma remained alive after either surgery (5 patients) or cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (1 patient).
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice